EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access

Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Lisa Bodei, Marta Cremonesi, Mahila Ferrari, Erik S Mittra, Harshad R Kulkarni, Christophe M Deroose, Rajaventhan Srirajaskanthan, John Ramage, Chiara Maria Grana, Francesca Botta, Matthias M Weber, Matthias Miederer und 7 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268903 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Lisa Bodei und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; bodeil@mskcc.org. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds, Octreotide. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOrganometallic CompoundsOctreotideHumansMaleFemaleMiddle AgedRadiometryAgedAdultSingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

[177Lu]Lu-DOTATATEdosimetryneuroendocrine tumorspeptide receptor radionuclide therapyradiopharmaceutical therapy

Substanzen

lutetium Lu 177 dotatateOrganometallic CompoundsOctreotide

Autor:innen und Institutionen

  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; bodeil@mskcc.org.
  • Radiation Research Unit, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • Medical Physics Unit, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • Division of Molecular Imaging and Therapy, Oregon Health and Science University, Portland, Oregon.
  • Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
  • Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.

Förderung

  • NCI NIH HHS

Zitieren

APA

Bodei, L., Cremonesi, M., Ferrari, M., Mittra, E. S., Kulkarni, H. R., Deroose, C. M., Srirajaskanthan, R., Ramage, J., Grana, C. M., Botta, F., Weber, M. M., Miederer, M., Reddy, R., Chicco, D., Mariani, M. F., Demange, A., Erion, J. L., Gericke, G., & Krenning, E. (2025). Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268903

Vancouver

Bodei L, Cremonesi M, Ferrari M, Mittra ES, Kulkarni HR, Deroose CM, et al. Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268903

BibTeX
@article{Bodei2025,
  author = {Bodei, Lisa and Cremonesi, Marta and Ferrari, Mahila and Mittra, Erik S and Kulkarni, Harshad R and Deroose, Christophe M and Srirajaskanthan, Rajaventhan and Ramage, John and Grana, Chiara Maria and Botta, Francesca and Weber, Matthias M and Miederer, Matthias and Reddy, Ryan and Chicco, Daniela and Mariani, Maurizio F and Demange, Arnaud and Erion, Jack L and Gericke, Germo and Krenning, Eric},
  title = {Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268903}
}
Kostenlos starten →